Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Oral TPOXX in Adults
NCT04971109Phase 3Completed
- Sponsor
- SIGA Technologies
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tecovirimat in smallpox, sponsored by SIGA Technologies. Started Mar 2022; status: completed.
02
Drugs
tecovirimat
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT04971109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971109.